Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report

Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Iafolla, Marco AJ, Ramsay, Jennifer, Wismer, Judy, McWhirter, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
JCMS case report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537058/
https://www.ncbi.nlm.nih.gov/pubmed/31205706
http://dx.doi.org/10.1177/2050313X19847358
_version_ 1783421920245448704
author Iafolla, Marco AJ
Ramsay, Jennifer
Wismer, Judy
McWhirter, Elaine
author_facet Iafolla, Marco AJ
Ramsay, Jennifer
Wismer, Judy
McWhirter, Elaine
author_sort Iafolla, Marco AJ
collection PubMed
description Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed granulomatous dermatitis and erythema induratum when treated with combination BRAF (vemurafenib) and MEK inhibitor (cobimetinib) therapy and discuss the clinical features and management of dermatologic side-effects secondary to BRAF +/– MEK inhibition.
format Online
Article
Text
id pubmed-6537058
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65370582019-06-14 Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report Iafolla, Marco AJ Ramsay, Jennifer Wismer, Judy McWhirter, Elaine SAGE Open Med Case Rep JCMS case report Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed granulomatous dermatitis and erythema induratum when treated with combination BRAF (vemurafenib) and MEK inhibitor (cobimetinib) therapy and discuss the clinical features and management of dermatologic side-effects secondary to BRAF +/– MEK inhibition. SAGE Publications 2019-05-16 /pmc/articles/PMC6537058/ /pubmed/31205706 http://dx.doi.org/10.1177/2050313X19847358 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle JCMS case report
Iafolla, Marco AJ
Ramsay, Jennifer
Wismer, Judy
McWhirter, Elaine
Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
title Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
title_full Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
title_fullStr Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
title_full_unstemmed Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
title_short Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
title_sort cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: a case report
topic JCMS case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537058/
https://www.ncbi.nlm.nih.gov/pubmed/31205706
http://dx.doi.org/10.1177/2050313X19847358
work_keys_str_mv AT iafollamarcoaj cobimetinibandvemurafenibinducedgranulomatousdermatitisanderythemainduratumacasereport
AT ramsayjennifer cobimetinibandvemurafenibinducedgranulomatousdermatitisanderythemainduratumacasereport
AT wismerjudy cobimetinibandvemurafenibinducedgranulomatousdermatitisanderythemainduratumacasereport
AT mcwhirterelaine cobimetinibandvemurafenibinducedgranulomatousdermatitisanderythemainduratumacasereport

Ejemplares similares